Q4 EPS Estimates for Globus Medical Increased by Analyst

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research lifted their Q4 2026 earnings estimates for Globus Medical in a research report issued on Monday, June 22nd. Zacks Research analyst Team now forecasts that the medical device company will post earnings of $1.33 per share for the quarter, up from their prior estimate of $1.32. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.74 per share.

Other analysts have also recently issued research reports about the company. Royal Bank Of Canada lifted their price objective on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Needham & Company LLC boosted their price target on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Barclays increased their price objective on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Wells Fargo & Company cut their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $105.00.

Globus Medical Trading Up 1.1%

NYSE GMED opened at $80.07 on Wednesday. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40. The firm’s fifty day simple moving average is $84.16 and its 200-day simple moving average is $87.51. The company has a market capitalization of $10.87 billion, a PE ratio of 18.62, a price-to-earnings-growth ratio of 1.63 and a beta of 0.95.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Invesco Ltd. boosted its holdings in Globus Medical by 1,235.2% during the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after acquiring an additional 3,595,339 shares during the period. Bank of Montreal Can grew its position in shares of Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after purchasing an additional 3,351,380 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after purchasing an additional 1,908,795 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new position in shares of Globus Medical during the 4th quarter worth about $90,411,000. Finally, Norges Bank acquired a new position in shares of Globus Medical during the 4th quarter worth about $89,922,000. 95.16% of the stock is owned by institutional investors.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 18.38% of the stock is owned by corporate insiders.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised its EPS forecasts for Globus Medical across several periods, including Q3 2026, Q1 2027, Q2 2027, FY2027, and FY2028, signaling improving earnings expectations.
• Positive Sentiment: The analyst firm maintained a Strong-Buy rating, which can support investor confidence in Globus Medical’s growth outlook.
• Neutral Sentiment: Several recent Zacks articles also discussed GMED’s valuation and macro/currency headwinds, suggesting the company still faces some growth and margin pressures despite the favorable estimate revisions. Article Title
• Neutral Sentiment: An earlier article noted GMED’s Q1 beat and the potential impact of foreign exchange pressures, which may keep investors focused on margin trends as well as revenue growth. Article Title
• Negative Sentiment: One Zacks update slightly lowered Q4 2027 EPS estimates, a small cautionary note, though it was offset by upgrades elsewhere.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.